Evolus Grants Restricted Stock Units to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy EOLS?
Source: Newsfilter
- Employee Incentive Program: Evolus granted 85,516 restricted stock units (RSUs) and 8,635 stock options to 10 newly hired non-executive employees in March 2026, aiming to attract and retain talent, thereby enhancing the company's competitive edge in the aesthetics market.
- Grant Details: The awards have grant and vesting commencement dates in March 2026, complying with Nasdaq Listing Rule 5635(c)(4), and will vest based on the requirement for employees to remain continuously employed on each vesting date, ensuring commitment to the company.
- Option Exercise Price: The stock options have an exercise price equal to the closing price on the last business day prior to the grant date, a strategy that aligns the interests of new employees with those of shareholders, promoting long-term company growth.
- Company Background: Evolus is a global performance beauty company focused on redefining the aesthetic injectable market through its flagship products Jeuveau® and Evolysse™, aiming to become a leader in the field and increase its market share in the rapidly growing aesthetics industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EOLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EOLS
Wall Street analysts forecast EOLS stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.390
Low
18.00
Averages
19.25
High
20.00
Current: 6.390
Low
18.00
Averages
19.25
High
20.00
About EOLS
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolus Q1 2026 Earnings Call Highlights
- Financial Performance: In Q1 2026, Evolus reported global net revenue of $73.1 million, including $66.4 million from Jeuveau and $6.7 million from Evolysse, indicating stable performance despite ongoing market challenges.
- Profitability Improvement: The company achieved positive adjusted EBITDA of $0.6 million in Q1, a significant turnaround from a loss of $5.5 million in the prior year, demonstrating progress in profitability and boosting investor confidence.
- Market Share Maintenance: Evolus maintained a 14% market share in the U.S. Jeuveau market while gaining share with Evolysse, showcasing strong positioning and growth potential in a competitive landscape.
- Future Outlook: Management reiterated the full-year revenue guidance of $327 million to $337 million and a low to mid-single-digit adjusted EBITDA margin, reflecting confidence in future growth, particularly with the upcoming Estyme launch and other pipeline milestones.
See More
Evolus Q1 Earnings Beat Expectations with Positive Outlook
- Strong Earnings Report: Evolus reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.06, indicating an improvement in profitability that boosts market confidence in its future performance.
- Revenue Growth: The company achieved Q1 revenue of $73.1 million, a 6.7% year-over-year increase, surpassing market expectations by $0.93 million, demonstrating strong growth momentum in a competitive market.
- Positive Outlook: Evolus projects total net revenues for 2026 to be between $327 million and $337 million, reflecting a 10% to 13% growth over the previous year, showcasing the company's confidence in its strategic planning for future growth.
- Cost Management: The adjusted gross profit margin for 2026 is expected to be between 65.5% and 67.0%, with non-GAAP operating expenses projected between $210 million and $216 million, indicating effective cost control while maintaining operational efficiency.
See More
Evolus Set to Announce Q1 Earnings on May 4th
- Earnings Announcement: Evolus is set to release its Q1 earnings on May 4th after market close, with a consensus EPS estimate of -$0.12, reflecting a 60% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $72.17 million, representing a 5.4% year-over-year increase, although the revenue estimates have faced four downward revisions in the last three months, suggesting market caution regarding short-term performance.
- Estimate Revisions: Over the past three months, Evolus has seen two upward revisions in EPS estimates with no downward adjustments, indicating growing analyst confidence in the company's profitability, while revenue estimates have remained unchanged, highlighting concerns over revenue growth.
- Future Guidance: Evolus has provided a revenue guidance range of $327 million to $337 million for 2026, demonstrating its strategic intent to expand its international presence and product portfolio, despite current revenue expectations facing challenges.
See More
Telix Appoints David Gill as Non-Executive Director
- Board Expansion: Telix announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the board's succession planning and governance structure.
- Extensive Industry Experience: With over 35 years in life sciences, Gill has held CFO and President roles in multiple public companies, expected to bring valuable capital markets and corporate turnaround expertise to Telix.
- Future Leadership Role: Gill is anticipated to succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring continuity and stability in leadership.
- Strategic Growth Plans: Telix intends to strengthen governance through additional board appointments to support its growth trajectory as a dual-listed company, reflecting a positive outlook for future developments.
See More
Telix Pharmaceuticals Appoints New Non-Executive Director
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the board's succession planning and expansion to improve corporate governance.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held senior management roles in various biopharmaceutical and medical device companies, and his deep capital markets expertise is expected to provide strategic advantages for Telix.
- Future Leadership Role: Gill is anticipated to succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring continuity and stability in the company's leadership.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is expected to aid the company's expansion in global markets, particularly in addressing significant unmet medical needs in oncology and rare diseases.
See More
Telix Appoints New Director to Strengthen Governance
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the company's governance structure and paving the way for future succession planning.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held CFO or President roles in multiple publicly traded companies, expected to bring deep capital market knowledge and corporate turnaround strategies to Telix.
- Strategic Leadership Change: Gill will succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring stability and continuity during the leadership transition for the company.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is anticipated to aid the company's expansion in global markets, particularly in key regions like the U.S. and Europe.
See More
Evolus Q1 2026 Earnings Call Highlights
- Financial Performance: In Q1 2026, Evolus reported global net revenue of $73.1 million, including $66.4 million from Jeuveau and $6.7 million from Evolysse, indicating stable performance despite ongoing market challenges.
- Profitability Improvement: The company achieved positive adjusted EBITDA of $0.6 million in Q1, a significant turnaround from a loss of $5.5 million in the prior year, demonstrating progress in profitability and boosting investor confidence.
- Market Share Maintenance: Evolus maintained a 14% market share in the U.S. Jeuveau market while gaining share with Evolysse, showcasing strong positioning and growth potential in a competitive landscape.
- Future Outlook: Management reiterated the full-year revenue guidance of $327 million to $337 million and a low to mid-single-digit adjusted EBITDA margin, reflecting confidence in future growth, particularly with the upcoming Estyme launch and other pipeline milestones.
See More
Evolus Q1 Earnings Beat Expectations with Positive Outlook
- Strong Earnings Report: Evolus reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.06, indicating an improvement in profitability that boosts market confidence in its future performance.
- Revenue Growth: The company achieved Q1 revenue of $73.1 million, a 6.7% year-over-year increase, surpassing market expectations by $0.93 million, demonstrating strong growth momentum in a competitive market.
- Positive Outlook: Evolus projects total net revenues for 2026 to be between $327 million and $337 million, reflecting a 10% to 13% growth over the previous year, showcasing the company's confidence in its strategic planning for future growth.
- Cost Management: The adjusted gross profit margin for 2026 is expected to be between 65.5% and 67.0%, with non-GAAP operating expenses projected between $210 million and $216 million, indicating effective cost control while maintaining operational efficiency.
See More
Evolus Set to Announce Q1 Earnings on May 4th
- Earnings Announcement: Evolus is set to release its Q1 earnings on May 4th after market close, with a consensus EPS estimate of -$0.12, reflecting a 60% year-over-year improvement, indicating potential recovery in profitability.
- Revenue Expectations: The anticipated revenue for Q1 is $72.17 million, representing a 5.4% year-over-year increase, although the revenue estimates have faced four downward revisions in the last three months, suggesting market caution regarding short-term performance.
- Estimate Revisions: Over the past three months, Evolus has seen two upward revisions in EPS estimates with no downward adjustments, indicating growing analyst confidence in the company's profitability, while revenue estimates have remained unchanged, highlighting concerns over revenue growth.
- Future Guidance: Evolus has provided a revenue guidance range of $327 million to $337 million for 2026, demonstrating its strategic intent to expand its international presence and product portfolio, despite current revenue expectations facing challenges.
See More
Telix Appoints David Gill as Non-Executive Director
- Board Expansion: Telix announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the board's succession planning and governance structure.
- Extensive Industry Experience: With over 35 years in life sciences, Gill has held CFO and President roles in multiple public companies, expected to bring valuable capital markets and corporate turnaround expertise to Telix.
- Future Leadership Role: Gill is anticipated to succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring continuity and stability in leadership.
- Strategic Growth Plans: Telix intends to strengthen governance through additional board appointments to support its growth trajectory as a dual-listed company, reflecting a positive outlook for future developments.
See More
Telix Pharmaceuticals Appoints New Non-Executive Director
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the board's succession planning and expansion to improve corporate governance.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held senior management roles in various biopharmaceutical and medical device companies, and his deep capital markets expertise is expected to provide strategic advantages for Telix.
- Future Leadership Role: Gill is anticipated to succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring continuity and stability in the company's leadership.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is expected to aid the company's expansion in global markets, particularly in addressing significant unmet medical needs in oncology and rare diseases.
See More
Telix Appoints New Director to Strengthen Governance
- Board Expansion: Telix Pharmaceuticals announces the appointment of David Gill as a Non-Executive Director effective May 11, 2026, aimed at enhancing the company's governance structure and paving the way for future succession planning.
- Extensive Industry Experience: With over 35 years in the life sciences sector, Gill has held CFO or President roles in multiple publicly traded companies, expected to bring deep capital market knowledge and corporate turnaround strategies to Telix.
- Strategic Leadership Change: Gill will succeed current Chair Mark Nelson, who will remain on the board as a Non-Executive Director, ensuring stability and continuity during the leadership transition for the company.
- Global Business Development: Telix focuses on the development and commercialization of radiopharmaceuticals, and Gill's addition is anticipated to aid the company's expansion in global markets, particularly in key regions like the U.S. and Europe.
See More
